Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?

Laboratory hematology : official publication of the International Society for Laboratory Hematology - 1 Mar 2011

Lopes da Silva Rodrigo, Ribeiro Patricia, Lourenço Alexandra, Santos Susana Costa, Santos Margarida, Costa Isabel, de Sousa Aida Botelho

Abstract excerpt

BACKGROUND AND OBJECTIVES: The role of the Janus kinase 2 V617F (JAK2(V617F)) mutation in the pathogenesis of the various BCR-ABL1-negative myeloproliferative neoplasms (MPNs) remains unclear. Its significance in leukemic transformation is a matter of even greater controversy. The aim of this study was to evaluate both the JAK2(V617F) mutational status of the rare cases in which blast crisis occurred in our...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cell Transformation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ABL1 gene

Share to Janus Kinase 2

Share to Mutation

Share to Myeloproliferative Disorders

Share to Treatment Outcome

Source

Identifiers

PMID: 21421540
DOI: 10.1532/LH96.10018

Genes

JAK2
ABL1
BCR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?PMID 21421540Read ↗

Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasmSemantic proximity Read ↗

Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?Semantic proximity Read ↗

JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?Semantic proximity Read ↗

The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis.Semantic proximity Read ↗

Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.Semantic proximity Read ↗

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.Semantic proximity Read ↗

Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome.Semantic proximity Read ↗

Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes.Semantic proximity Read ↗

A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.Semantic proximity Read ↗

The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.Semantic proximity Read ↗

A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.Semantic proximity Read ↗

JAK-2 mutations and their relevance to myeloproliferative diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.